Entellus Medical Inc (ENTL) VP Sells $23,241.68 in Stock

Entellus Medical Inc (NASDAQ:ENTL) VP Thomas P. Williamson sold 968 shares of Entellus Medical stock in a transaction on Friday, January 5th. The shares were sold at an average price of $24.01, for a total transaction of $23,241.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas P. Williamson also recently made the following trade(s):

  • On Monday, January 8th, Thomas P. Williamson sold 2,449 shares of Entellus Medical stock. The shares were sold at an average price of $24.08, for a total transaction of $58,971.92.

Shares of Entellus Medical Inc (NASDAQ:ENTL) opened at $24.13 on Friday. Entellus Medical Inc has a 1 year low of $11.47 and a 1 year high of $25.58. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. The company has a market cap of $614.43 and a PE ratio of -18.85.

Several institutional investors have recently added to or reduced their stakes in ENTL. Nationwide Fund Advisors boosted its position in shares of Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after buying an additional 2,635 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Entellus Medical by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock valued at $168,000 after purchasing an additional 5,605 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after purchasing an additional 4,533 shares during the last quarter. Kopp Investment Advisors LLC raised its stake in Entellus Medical by 0.5% in the 2nd quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after purchasing an additional 55 shares during the last quarter. Finally, Rhumbline Advisers acquired a new position in Entellus Medical in the 2nd quarter valued at about $199,000. Institutional investors and hedge funds own 78.76% of the company’s stock.

ENTL has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. TheStreet upgraded shares of Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. William Blair lowered shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Canaccord Genuity restated a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a research report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $19.25.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/01/12/entellus-medical-inc-entl-vp-sells-23241-68-in-stock.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply